27 min listen
How established biologics become less safe
FromThe BMJ Podcast
ratings:
Length:
17 minutes
Released:
Apr 28, 2017
Format:
Podcast episode
Description
Biologics have revolutionised healthcare for some conditions - but have been expensive because of the multistep manufacturing processes required to create these complex molecules.
Changes to the manufacturing of biological agents make them more affordable, but can lead to drugs with different components from the original medicine tested in clinical trials, challenging assumptions about safety.
David Hunt, honorary consultant neurologist and Wellcome Trust intermediate clinical fellow, at the University of Edinburgh, joins us to describe how that happens and what the result can be.
Read the full analysis:
http://www.bmj.com/content/357/bmj.j1707
Changes to the manufacturing of biological agents make them more affordable, but can lead to drugs with different components from the original medicine tested in clinical trials, challenging assumptions about safety.
David Hunt, honorary consultant neurologist and Wellcome Trust intermediate clinical fellow, at the University of Edinburgh, joins us to describe how that happens and what the result can be.
Read the full analysis:
http://www.bmj.com/content/357/bmj.j1707
Released:
Apr 28, 2017
Format:
Podcast episode
Titles in the series (100)
Plain Packaging: Plain packaging on tobacco products is the latest strategy aimed at reducing smoking. Campaigners had hoped the UK would follow Australia’s example. But they have been disappointed as the UK government postpones the plans until “more evidence” is ava... by The BMJ Podcast